Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 3Recurrence 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Waldenstrom Macroglobulinemia 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Polyneuropathies 1Paraproteinemias 1Mouth Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Endocrine System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Temozolomide 11Radiotherapy 11Filgrastim 6Granulocyte Colony-Stimulating Factor 4Chemotherapy, Adjuvant 4etoposide phosphate 3Topotecan 3O(6)-benzylguanine 3Melphalan 3Etoposide 3Cyclophosphamide 3Carboplatin 3sodium thiosulfate 2sargramostim 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Methylphenidate 2Mannitol 2Ifosfamide 2Carmustine 2Busulfan 2Bone Marrow Transplantation 2Bevacizumab 2transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1temsirolimus 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1poly ICLC 1pentetreotide 1pemigatinib 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Central Nervous System Neoplasms × Thalidomide × Clear all
NCT00014443 2023-01-09

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Rush University Medical Center

Phase 2 Terminated
5 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡